Edition:
United Kingdom

Chembio Diagnostics Inc (CEMI.OQ)

CEMI.OQ on NASDAQ Stock Exchange Capital Market

5.88USD
16 Jul 2019
Change (% chg)

-- (--)
Prev Close
$5.88
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,941
52-wk High
$11.55
52-wk Low
$4.87

Latest Key Developments (Source: Significant Developments)

Chembio Diagnostics Sees FY 2018 Revenue Of $33.1 Mln TO $33.4 Mln
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2018 REVENUE.SEES FY 2018 REVENUE $33.1 MILLION TO $33.4 MILLION.SEES Q4 2018 REVENUE $7.3 MILLION TO $7.6 MILLION.Q4 REVENUE VIEW $7.1 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $32.7 MILLION -- REFINITIV IBES DATA.EXPECTS TO ACHIEVE FULL YEAR REVENUE OF $100 MILLION IN 2023 AND TO ACHIEVE A GROSS MARGIN OF 50% BY YEAR END 2023.  Full Article

Chembio Diagnostics Q3 Loss Per Share $0.16
Thursday, 8 Nov 2018 

Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.16.Q3 REVENUE ROSE 24 PERCENT TO $9.4 MILLION.  Full Article

Chembio Diagnostics Announces Pricing Of Its Public Offering Of Common Stock
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK.CHEMBIO DIAGNOSTICS - PRICING OF UNDERWRITTEN REGISTERED PUBLIC OFFERING OF 2.4 MILLION SHARES OF ITS COMMON STOCK AT OFFERING PRICE OF $6.75 PER SHARE.  Full Article

Chembio Diagnostics Inc - May Offer From Time To Time Common Stock, Preferred Stock, Warrants And Units - SEC Filing
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS INC - MAY OFFER FROM TIME TO TIME COMMON STOCK, PREFERRED STOCK, WARRANTS AND UNITS - SEC FILING.CHEMBIO DIAGNOSTICS-MAY ALSO ISSUE ANY OF COMMON STOCK, PREFERRED STOCK, WARRANTS OR UNITS UPON CONVERSION, EXCHANGE OR EXERCISE OF ANY OF SECURITIES.CHEMBIO DIAGNOSTICS INC - AGGREGATE INITIAL OFFERING PRICE OF THE SECURITIES THAT WE OFFER WILL NOT EXCEED $50 MILLION.  Full Article

Chembio Diagnostics Q4 Loss Per Share $0.16
Thursday, 8 Mar 2018 

March 8 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.16.Q4 REVENUE ROSE 40.7 PERCENT TO $6.0 MILLION.  Full Article

Chembio Diagnostics Announces Pricing Of Its Public Offering Of Common Stock
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.78 MILLION COMMON SHARES PRICED AT $6.75PER SHARE.  Full Article

Chembio Diagnostics Announces Proposed Public Offering Of Common Stock
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CHEMBIO DIAGNOSTICS INC - ‍COMMENCED AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF ITS COMMON STOCK​.  Full Article

Chembio Diagnostics Announces Major New Tender Win And Certain Preliminary 2017 Financial Results
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES MAJOR NEW TENDER WIN AND CERTAIN PRELIMINARY 2017 FINANCIAL RESULTS.SEES FY 2017 REVENUE $23.7 MILLION TO $24 MILLION.CHEMBIO - ‍WON 3-YEAR TENDER FROM ETHIOPIA PHARMACEUTICALS FUND AND SUPPLY AGENCY TO DELIVER HIV 1/2 STAT-PAK ASSAY WITH CONTRACT VALUE $15.8 MILLION​.‍COMPANY EXPECTS SHIPMENTS TO BEGIN DURING Q2 OF 2018 FOR ETHIOPIA PHARMACEUTICALS FUND AND SUPPLY AGENCY CONTRACT​.‍CASH AND CASH EQUIVALENTS ARE ESTIMATED TO BE APPROXIMATELY $3.7 MILLION AS OF DECEMBER 31, 2017​.  Full Article

Chembio Diagnostics Appoints Neil Goldman As CFO
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES APPOINTMENT OF NEIL A. GOLDMAN AS CHIEF FINANCIAL OFFICER.CHEMBIO DIAGNOSTICS - GOLDMAN SUCCEEDS RICHARD J. LARKIN, WHO HAS SERVED AS CO'S EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER SINCE 2003.  Full Article

Chembio Diagnostics And Astrazeneca Collaborates To Develop Point-Of-Care Diagnostic Test
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Astrazeneca Plc ::CHEMBIO DIAGNOSTICS AND ASTRAZENECA ENTER A COLLABORATION TO DEVELOP POINT-OF-CARE DIAGNOSTIC TEST.CHEMBIO DIAGNOSTICS INC - UNDER TERMS OF 18-MONTH AGREEMENT, CO WILL RECEIVE UP TO $2.9 MILLION IN FUNDING FROM ASTRAZENECA.  Full Article